Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TOACT)
Background: Endovascular thrombolysis, with or without mechanical clot removal (ET), may be beneficial for a subgroup of patients with cerebral venous sinus thrombosis (CVT), who have a poor prognosis despite treatment with heparin. Published experience with ET is promising, but only based on case series and not on controlled trials.
Objective: The main objective of the TO-ACT trial is to determine if ET improves the functional outcome of patients with a severe form of CVT
Study design: The TO-ACT trial will be designed as a multi-centre, prospective, randomized, open-label, blinded endpoint (PROBE) trial.
Study population: Patients are eligible if they have a radiologically proven CVT, a high probability of poor outcome (defined by presence of one or more of the following risk factors: mental status disorder, coma, intracranial hemorrhagic lesion or thrombosis of the deep cerebral venous system) and the responsible physician is uncertain if ET or standard anti-coagulant treatment is better.
Intervention: Patients will be randomized to receive either ET or standard therapy (therapeutic doses of heparin). ET consists of local application of alteplase or urokinase within the thrombosed sinuses, and/or mechanical thrombectomy. Glasgow coma score, NIH stroke scale and relevant laboratory parameters will be assessed at baseline.
Endpoints: The primary endpoint is the modified Rankin scale (mRS) at 12 months. The most important secondary outcomes are the mRS, mortality and recanalization rate at 6 months. Major intra- and extracranial hemorrhagic complications within one week following the intervention are the principal safety outcome. Results will be analyzed according to the "intention-to-treat" principle. Assessment of study endpoints will be carried out according to standardized questionnaires by a blinded neurologist or research nurse who is not involved in the treatment of the patient.
Study size: To detect a 50% relative reduction in mRS≥2 (from 40 to 20%), 164 patients (82 in each treatment arm) have to be included (two-sided alpha, 80% power).
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Included patients may benefit directly from ET. Complications of ET, most notably intracranial hemorrhages, constitute the most important risk of the study.
Sinus Thrombosis, Intracranial
Drug: Endovascular thrombolysis
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TOACT)|
- Favorable clinical outcome (modified Rankin score 0-1) [ Time Frame: 12 months after randomization ] [ Designated as safety issue: Yes ]Outcome on the modified Rankin Scale (mortality included) at 12 months after randomization is considered the primary study outcome to determine the efficacy of thrombolytic treatment. For the primary endpoint the mRS will be dichotomized between 1 and 2 (i.e. incomplete recovery is defined as a score of 2 or higher, including death).
- Favorable clinical outcome (modified Rankin score 0-1) [ Time Frame: 6 months after randomization ] [ Designated as safety issue: Yes ]
- Recanalization rate of cerebral venous system [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- All cause mortality [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- Required surgical intervention in relation to CVT [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]The proportion of surgical intervention that are required in relation to cerebral venous thrombosis (e.g. ventricular shunting procedures or craniotomy)
- Major extracranial and symptomatic intracranial hemorrhagic complications [ Time Frame: 1 week after randomization ] [ Designated as safety issue: Yes ]Extracranial hemorrhage is classified as major if clinically overt and associated with fall in hemoglobin of 1.2 mmol/l (2 gram/dl) or more within 48 hours, if it is retroperitoneal, intracranial or intraocular, or requires a transfusion of two or more units of packed cells. Any bleeding requiring operation or leading to death is regarded as major. Symptomatic intracranial hemorrhage is defined as any apparently extravascular blood in the brain associated with an increase of 4 points or more on the NIHSS score, or leading to death.
- Dead or dependency (modified Rankin score 3-6) [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]
- Modified Rankin Scale at 1 month after randomization [ Time Frame: 1 month after randomization ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||January 2018|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
|Experimental: Endovascular thrombolysis||
Drug: Endovascular thrombolysis
Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
|Active Comparator: Standard treatment||
The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
Please refer to this study by its ClinicalTrials.gov identifier: NCT01204333
|Contact: Jan Stam, MDfirstname.lastname@example.org|
|Contact: Jonathan Coutinho, MDemail@example.com|
|Centre hospitalier de l'université de Montréal (CHUM)||Recruiting|
|Contact: S Lanthier|
|Contact: Ji Xunming, Prof. dr. 8683198127 firstname.lastname@example.org|
|Principal Investigator: Ji Xunming, Prof.dr.|
|Hôpital Lariboisière||Not yet recruiting|
|Contact: Isabelle Crassard, MD +31-20-5664591 email@example.com|
|Principal Investigator: Isabelle Crassard, MD|
|Academic Medical Centre||Recruiting|
|Contact: Jonathan Coutinho, MD +31-20-5664591 firstname.lastname@example.org|
|Principal Investigator: Jan Stam, MD|
|University Medical Centre Groningen||Recruiting|
|Contact: M Uyttenboogaart|
|St. Antonius hospital||Recruiting|
|Contact: W J Schonewille|
|Erasmus Medical Centre||Recruiting|
|Contact: D Dippel|
|The Hague, Netherlands|
|Contact: S F T M de Bruijn|
|Medical Centre Haaglanden||Recruiting|
|The Hague, Netherlands|
|Contact: K Jellema|
|Hospital de Braga||Recruiting|
|Contact: C Ferreira|
|Hospital da Universidade de Coimbra||Recruiting|
|Contact: L Cunha|
|Hospital Santa Maria||Recruiting|
|Contact: Jose M Ferro +31-20-5664591 email@example.com|
|Principal Investigator: Josse Ferro, MD, PhD|
|Hospital Sao Jose hospital||Recruiting|
|Contact: A P Nunes|
|Hospital de Santo António||Recruiting|
|Contact: M G Lopes|
|Inselspital, University Hospital||Recruiting|
|Contact: M Arnold, Prof. dr. +41 (0)31 632 33 32 Marcel.Arnold@insel.ch|
|Principal Investigator: M. Arnold, Prof. dr.|
|Study Chair:||Jan Stam, MD, PhD||Academic Medical Centre, Amsterdam, The Netherlands|
|Principal Investigator:||Jose M Ferro, MD, PhD||Hospital Santa Maria, Lisbon, Portugal|
|Principal Investigator:||Marie-Germaine Bousser, MD, PhD||Hôpital Lariboisière, Paris, France|
|Principal Investigator:||Patricia Canhão, MD, PhD||Hospital Santa Maria, Lisbon, Portugal|
|Principal Investigator:||Isabelle Crassard, MD, PhD||Hôpital Lariboisière, Paris, France|
|Principal Investigator:||Charles BL Majoie, MD, PhD||Academic Medical Centre, Amsterdam, The Netherlands|
|Principal Investigator:||Jim A Reekers, MD, PhD||Academic Medical Centre, Amsterdam, The Netherlands|
|Principal Investigator:||E Houdart, MD, PhD||Hôpital Lariboisière, Paris, France|
|Principal Investigator:||Rob J de Haan, PhD||Academic Medical Centre, Amsterdam, The Netherlands|